CeriBell (NASDAQ:CBLL) Coverage Initiated by Analysts at Bank of America

Bank of America initiated coverage on shares of CeriBell (NASDAQ:CBLL) in a research report sent to investors on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $32.00 price target on the stock.

Several other equities research analysts have also issued reports on the company. JPMorgan Chase & Co. initiated coverage on CeriBell in a report on Tuesday. They set an “overweight” rating and a $32.00 price target for the company. William Blair started coverage on shares of CeriBell in a research note on Tuesday. They issued an “outperform” rating for the company. Canaccord Genuity Group began coverage on shares of CeriBell in a report on Tuesday. They set a “buy” rating and a $30.00 price target on the stock. Finally, TD Cowen assumed coverage on shares of CeriBell in a report on Tuesday. They issued a “buy” rating and a $31.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell has an average rating of “Buy” and an average target price of $31.00.

CeriBell Trading Down 2.3 %

Shares of NASDAQ:CBLL opened at $28.27 on Tuesday. CeriBell has a 1 year low of $23.00 and a 1 year high of $29.53.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.